Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
116,964,738
-
Total 13F shares
-
87,967,283
-
Share change
-
-1,023,041
-
Total reported value
-
$1,615,322,964
-
Put/Call ratio
-
217%
-
Price per share
-
$18.34
-
Number of holders
-
200
-
Value change
-
-$17,575,985
-
Number of buys
-
111
-
Number of sells
-
83
Institutional Holders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) as of Q3 2020
As of 30 Sep 2020,
Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) was held by
200 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
87,967,283 shares.
The largest 10 holders included
BlackRock Inc., Temasek Holdings (Private) Ltd, JPMORGAN CHASE & CO, ALLIANCEBERNSTEIN L.P., STATE STREET CORP, VANGUARD GROUP INC, PERCEPTIVE ADVISORS LLC, Kohlberg Kravis Roberts & Co. L.P., AMERIPRISE FINANCIAL INC, and Camber Capital Management LP.
This page lists
200
institutional shareholders reporting positions in this security
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.